Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Pemvidutide.

Research draft

Pemvidutide is an investigational GLP-1 and glucagon receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Pemvidutide is an investigational GLP-1 and glucagon receptor agonist.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFOSynthetic peptide (dual agonist)
PRIMARY CONTEXTGLP-1 / glucagon dual agonist

Mechanism

It combines appetite and metabolic pathways relevant to weight and liver disease.

Human research

Randomised clinical research includes metabolic liver-disease outcomes; positive endpoints must be stated by trial and duration.

Preclinical & other research

Metabolic models support the dual-receptor rationale.

Safety & unknowns

Gastrointestinal symptoms and liver-disease context require trial-specific assessment.

Regulatory status

Investigational in reviewed sources; no broad authorisation is established here.

Reported use & evidence

Research profile draft

The supplied Pemvidutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds